Humacyte, Inc. (NASDAQ:HUMA) Given Average Recommendation of “Moderate Buy” by Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $8.1429.

HUMA has been the topic of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Monday, January 5th. UBS Group restated a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a report on Monday, December 1st. BTIG Research reissued a “buy” rating and set a $6.00 target price on shares of Humacyte in a report on Friday, November 21st. Finally, Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st.

Humacyte Stock Performance

Shares of HUMA stock opened at $1.12 on Friday. The firm has a market capitalization of $209.74 million, a price-to-earnings ratio of -4.87 and a beta of 1.93. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. The business has a fifty day moving average of $1.16 and a 200 day moving average of $1.60. Humacyte has a 1 year low of $0.91 and a 1 year high of $4.85.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. The firm had revenue of $0.75 million for the quarter, compared to analysts’ expectations of $0.92 million. As a group, research analysts expect that Humacyte will post -1.27 earnings per share for the current year.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Lazari Capital Management Inc. purchased a new stake in Humacyte in the 2nd quarter worth approximately $27,000. Prudential Financial Inc. acquired a new position in shares of Humacyte in the 2nd quarter valued at $28,000. Financial Advisors Network Inc. purchased a new stake in Humacyte during the second quarter worth $28,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Humacyte during the second quarter valued at $30,000. Finally, Valeo Financial Advisors LLC acquired a new stake in Humacyte during the second quarter valued at $32,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.